FibroBiologics Stock (NASDAQ:FBLG)

Ownership Financials Chart

Previous Close

$1.86

52W Range

$1.08 - $46.00

50D Avg

$3.49

200D Avg

$8.17

Market Cap

$73.48M

Avg Vol (3M)

$276.94K

Beta

-

Div Yield

-

FBLG Company Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Feb 01, 2024

Website

FBLG Performance

FBLG Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-8.89M	$-4.47M	$-1.58M
Net Income	$-16.48M	$-5.12M	$-1.58M
EBITDA	$-8.45M	$-4.37M	$-1.58M
Basic EPS	$-0.58	$-0.16	$-0.05
Diluted EPS	$-0.58	$-0.16	$-0.05

Fiscal year ends in Dec 23 | Currency in USD